NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).

被引：0

作者：

Tan, Antoinette R.

Buyse, Marc E.

Rastogi, Priya

Jacobs, Samuel A.

Robidoux, Andre

Flynn, Patrick J.

Thirlwell, Michael P.

Fehrenbacher, Louis

Stella, Philip J.

Goel, Rakesh

Julian, Thomas B.

Provencher, Louise

Bury, Martin Joseph

Paik, Soonmyung

Geyer, Charles E.

Swain, Sandra M.

Mamounas, Eleftherios P.

Wolmark, Norman

机构：

[1] Natl Surg Adjuvant Breast & Bowel Project, New Brunswick, NJ USA

[2] Canc Inst New Jersey, New Brunswick, NJ USA

[3] Int Inst Drug Dev, Louvain, Belgium

[4] NSABP, Pittsburgh, PA USA

[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA

[6] NSABP, Montreal, PQ, Canada

[7] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[8] NSABP, St Louis Pk, MN USA

[9] Metro Minnesota Community Clin Oncol Project, St Louis Pk, MN USA

[10] Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada

[11] NSABP, Vallejo, CA USA

[12] Kaiser Permanente Northern Calif, Vallejo, CA USA

[13] NSABP, Ann Arbor, MI USA

[14] St Joseph Mercy Hlth Syst, Ann Arbor, MI USA

[15] NSABP, Ottawa, ON, Canada

[16] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[17] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA

[18] NSABP, Quebec City, PQ, Canada

[19] Ctr Hosp Affilie Univ Quebec, Hop St Sacrement, Quebec City, PQ 75390, Canada

[20] NSABP, Grand Rapids, MI USA

[21] Grand Rapids Clin Oncol Program, Grand Rapids, MI USA

[22] NSABP, Dallas, TX USA

[23] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[24] NSABP, Washington, DC USA

[25] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA

[26] NSABP, Canton, OH USA

[27] Aultman Hosp, Canton, OH USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1025

引用

页数：1

共 50 条

[1] Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study
Tan, A. R.
Johannes, H.
Rastogi, P.
Jacobs, S. A.
Robidoux, A.
Flynn, P. J.
Thirlwell, M. P.
Fehrenbacher, L.
Stella, P. J.
Goel, R.
Julian, T. B.
Provencher, L.
Bury, M. J.
Bhatt, K.
Geyer, C. E., Jr.
Swain, S. M.
Mamounas, E. P.
Wolmark, N.
BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) : 163 - 169
[2] Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study
A. R. Tan
H. Johannes
P. Rastogi
S. A. Jacobs
A. Robidoux
P. J. Flynn
M. P. Thirlwell
L. Fehrenbacher
P. J. Stella
R. Goel
T. B. Julian
L. Provencher
M. J. Bury
K. Bhatt
C. E. Geyer
S. M. Swain
E. P. Mamounas
N. Wolmark
Breast Cancer Research and Treatment, 2015, 149 : 163 - 169
[3] Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel (WP) or eribulin (E) followed by doxorubicin and cyclophosphamide (AC) in women with locally advanced HER2-negative breast cancer (LABC): NSABP FB-9
Abraham, Jame
Robidoux, Andre
Tan, Antoinette R.
Buyse, Marc E.
Wolmark, Norman
Jacobs, Samuel A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4] A phase II clinical trail of four cycles of doxorubicin and cyclophosphamide followed by weekly paclitaxel given concurrently with pazopanib as neoadjuvant therapy followed by postoperative pazopanib for women with locally advanced breast cancer (LABC): A phase II trail of the NSABP Foundation Research Group (FB-6/VEG110264).
Rastogi, P.
Buyse, M. E.
Tan, A. R.
Jacobs, S. A.
Swain, S. M.
Geyer, C. E.
Wolmark, N.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[5] Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9
Abraham, Jame
Robidoux, Andr
Tan, Antoinette R.
Limentani, Steven
Sturtz, Keren
Shalaby, Ibrahim
Alcorn, Hope
Buyse, Marc E.
Wolmark, Norman
Jacobs, Samuel A.
BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (02) : 399 - 405
[6] Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9
Jame Abraham
André Robidoux
Antoinette R. Tan
Steven Limentani
Keren Sturtz
Ibrahim Shalaby
Hope Alcorn
Marc E. Buyse
Norman Wolmark
Samuel A. Jacobs
Breast Cancer Research and Treatment, 2015, 152 : 399 - 405
[7] Platinum compounds (PLcs) added to standard adjuvant or neoadjuvant regimen of doxorubicin plus cyclophosphamide (AC), followed by weekly paclitaxel (wP) in triple negative (TN), HER 2-neu positive (HER 2+) or locally advanced breast cancer (LABC)
Vassilaki, M.
Sioulas, A.
Tsantekidou, M.
Klitsa, A.
Desses, N.
Georgakopoulos, C.
Kosmidis, C.
Tsionou, C.
Parassiris, V.
Xepapadakis, G.
BREAST, 2011, 20 : S66 - S66
[8] Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group
Rastogi, P.
Buyse, M.
Swain, S.
Jacobs, S.
Robidoux, A.
Liepman, M.
Dy, P.
Geyer, C., Jr.
Wolmark, N.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[9] NSABP FB-7 Trial: A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel and Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer
Lu, J.
Jacobs, S. A.
Buyse, M. E.
Paik, S.
Wolmark, N.
CANCER RESEARCH, 2012, 72
[10] Phase II trial of docetaxel plus doxorubicin and cyclophosphamide in locally advanced breast cancer (LABC).
Puertolas, T
Grandez, R
de Lobera, AR
Lao, J
Herrero, A
Trufero, JM
Pazo, R
Orduña, VA
Cortes, AA
Torres, AA
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 89S - 89S

← 1 2 3 4 5 →